{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:27:12Z","timestamp":1769689632716,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T00:00:00Z","timestamp":1384819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s40291-013-0068-x","type":"journal-article","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T01:39:49Z","timestamp":1384825189000},"page":"105-116","source":"Crossref","is-referenced-by-count":14,"title":["Hexaminolevulinate Blue Light Cystoscopy: A Review of Its Use in the Diagnosis of Bladder Cancer"],"prefix":"10.1007","volume":"18","author":[{"given":"Lily P. H.","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,19]]},"reference":[{"issue":"4","key":"68_CR1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.eururo.2010.01.025","volume":"57","author":"JA Witjes","year":"2010","unstructured":"Witjes JA, Redorta JP, Jacqmin D, et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol. 2010;57(4):607\u201314.","journal-title":"Eur Urol."},{"key":"68_CR2","unstructured":"US National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bladder cancer (version 1.2013). 19 Nov 2012. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf . Accessed 28 May 2013."},{"issue":"3","key":"68_CR3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","volume":"27","author":"KD Sievert","year":"2009","unstructured":"Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27(3):295\u2013300.","journal-title":"World J Urol."},{"issue":"5","key":"68_CR4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","volume":"41","author":"M Brausi","year":"2002","unstructured":"Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523\u201331.","journal-title":"Eur Urol."},{"key":"68_CR5","unstructured":"International Consortium for Urologic Diseases\u2014European Association of Urology, Soloway M, Khoury S. International Consultation on Urologic Diseases: bladder cancer. 2nd ed. 2012. http:\/\/www.icud.info\/PDFs\/Bladder%20Cancer%20Second%20Edition%202012.pdf . Accessed 27 Sep 2013."},{"key":"68_CR6","unstructured":"European Association of Urology. Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Mar 2013. http:\/\/www.uroweb.org\/gls\/pdf\/05_TaT1_Bladder_Cancer_LR.pdf . Accessed 28 May 2013."},{"issue":"6","key":"68_CR7","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","volume":"186","author":"M Brausi","year":"2011","unstructured":"Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2011;186(6):2158\u201367.","journal-title":"J Urol."},{"issue":"1","key":"68_CR8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2012.09.057","volume":"63","author":"AM Kamat","year":"2013","unstructured":"Kamat AM, Hegarty PK, Gee JR, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol. 2013;63(1):4\u201315.","journal-title":"Eur Urol."},{"issue":"2","key":"68_CR9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.juro.2012.03.127","volume":"188","author":"JJ Liu","year":"2012","unstructured":"Liu JJ, Droller MJ, Liao JC. New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol. 2012;188(2):361\u20138.","journal-title":"J Urol."},{"issue":"5","key":"68_CR10","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1021\/cr900300p","volume":"110","author":"JP Celli","year":"2010","unstructured":"Celli JP, Spring BQ, Rizvi I, et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev. 2010;110(5):2795\u2013838.","journal-title":"Chem Rev."},{"issue":"5","key":"68_CR11","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.3390\/molecules16054140","volume":"16","author":"M Wachowska","year":"2011","unstructured":"Wachowska M, Muchowicz A, Firczuk M, et al. Aminolevulinic acid (ALA) as a prodrug in photodynamic therapy of cancer. Molecules. 2011;16(5):4140\u201364.","journal-title":"Molecules."},{"issue":"3","key":"68_CR12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eursup.2010.02.007","volume":"9","author":"B Bordier","year":"2010","unstructured":"Bordier B, Mazerolles C, Malavaud B. Photodynamic diagnosis in non-muscle-invasive bladder cancer. Eur Urol Suppl. 2010;9(3):411\u20138.","journal-title":"Eur Urol Suppl."},{"key":"68_CR13","unstructured":"Photocure ASA. Cysview (hexaminolevulinate HCl): US prescribing information. Nov 2011. http:\/\/www.cysview.com\/wp-content\/uploads\/2013\/08\/Prescribing-Information.pdf . Accessed 3 Oct 2013."},{"key":"68_CR14","unstructured":"Ipsen Ltd. Hexvix 85\u00a0mg: summary of product characteristics. 15 Apr 2013. http:\/\/www.medicines.org.uk\/emc\/medicine\/27028\/SPC\/Hexvix+85mg\/ . Accessed 23 May 2013."},{"issue":"2","key":"68_CR15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MOU.0b013e3283501869","volume":"22","author":"NS Berg van den","year":"2012","unstructured":"van den Berg NS, van Leeuwen FW, van der Poel HG. Fluorescence guidance in urologic surgery. Curr Opin Urol. 2012;22(2):109\u201320.","journal-title":"Curr Opin Urol."},{"issue":"1\u20132","key":"68_CR16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bjc.6690338","volume":"80","author":"N Lange","year":"1999","unstructured":"Lange N, Jichlinski P, Zellweger M, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer. 1999;80(1\u20132):185\u201393.","journal-title":"Br J Cancer."},{"issue":"4","key":"68_CR17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.eururo.2013.07.007","volume":"64","author":"M Rink","year":"2013","unstructured":"Rink M, Babjuk M, Catto JW, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013;64(4):624\u201338.","journal-title":"Eur Urol."},{"issue":"4","key":"68_CR18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2165\/00003495-200666040-00010","volume":"66","author":"JE Frampton","year":"2006","unstructured":"Frampton JE, Plosker GL. Hexyl aminolevulinate: in the detection of bladder cancer. Drugs. 2006;66(4):571\u20138.","journal-title":"Drugs."},{"issue":"2","key":"68_CR19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0022-5347(05)68625-9","volume":"162","author":"A Marti","year":"1999","unstructured":"Marti A, Lange N, van den Bergh H, et al. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J Urol. 1999;162(2):546\u201352.","journal-title":"J Urol."},{"issue":"2 Pt 1","key":"68_CR20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/01.ju.0000075054.38441.2d","volume":"170","author":"A Marti","year":"2003","unstructured":"Marti A, Jichlinski P, Lange N, et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol. 2003;170(2 Pt 1):428\u201332.","journal-title":"J Urol."},{"issue":"4","key":"68_CR21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/0091270006286849","volume":"46","author":"B Klem","year":"2006","unstructured":"Klem B, Lappin G, Nicholson S, et al. Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers. J Clin Pharmacol. 2006;46(4):456\u201360.","journal-title":"J Clin Pharmacol."},{"issue":"3","key":"68_CR22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00126839-200607030-00005","volume":"7","author":"S Collaud","year":"2006","unstructured":"Collaud S, Jichlinski P, Marti A, et al. An open pharmacokinetic study of hexylaminolevulinate-induced photodiagnosis after intravesical administration. Drugs R D. 2006;7(3):173\u201386.","journal-title":"Drugs R D."},{"issue":"8","key":"68_CR23","first-page":"1481","volume":"57","author":"JM Gaullier","year":"1997","unstructured":"Gaullier JM, Berg K, Peng Q, et al. Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res. 1997;57(8):1481\u20136.","journal-title":"Cancer Res."},{"issue":"1","key":"68_CR24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2007.03.028","volume":"178","author":"Y Fradet","year":"2007","unstructured":"Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178(1):68\u201373.","journal-title":"J Urol."},{"issue":"1","key":"68_CR25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.juro.2007.03.034","volume":"178","author":"HB Grossman","year":"2007","unstructured":"Grossman HB, Gomella L, Fradet Y, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007;178(1):62\u20137.","journal-title":"J Urol."},{"issue":"3","key":"68_CR26","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/01.ju.0000169257.19841.2a","volume":"174","author":"D Jocham","year":"2005","unstructured":"Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005;174(3):862\u20136.","journal-title":"J Urol."},{"issue":"1","key":"68_CR27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.ju.0000100480.70769.0e","volume":"171","author":"J Schmidbauer","year":"2004","unstructured":"Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004;171(1):135\u20138.","journal-title":"J Urol."},{"issue":"8","key":"68_CR28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.acuro.2011.03.003","volume":"35","author":"JP Burgu\u00e9s","year":"2011","unstructured":"Burgu\u00e9s JP, Conde G, Oliva J, et al. Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group. Actas Urol Esp. 2011;35(8):439\u201345.","journal-title":"Actas Urol Esp."},{"issue":"3","key":"68_CR29","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.urology.2010.02.067","volume":"76","author":"B Geavlete","year":"2010","unstructured":"Geavlete B, Jecu M, Multescu R, et al. HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer: re-TURBT recurrence rates in a prospective, randomized study. Urology. 2010;76(3):664\u20139.","journal-title":"Urology."},{"issue":"4","key":"68_CR30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1464-410X.2011.10374.x","volume":"109","author":"B Geavlete","year":"2012","unstructured":"Geavlete B, Multescu R, Georgescu D, et al. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int. 2012;109(4):549\u201356.","journal-title":"BJU Int."},{"issue":"8 Pt 2","key":"68_CR31","doi-asserted-by":"crossref","first-page":"E297","DOI":"10.1111\/j.1464-410X.2011.10090.x","volume":"108","author":"GG Hermann","year":"2011","unstructured":"Hermann GG, Mogensen K, Carlsson S, et al. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta\/T1 patients: a randomized two-centre study. BJU Int. 2011;108(8 Pt 2):E297\u2013303.","journal-title":"BJU Int."},{"key":"68_CR32","doi-asserted-by":"crossref","unstructured":"Karaolides T, Skolarikos A, Bourdoumis A, et al. Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology. 2012;80(2):354\u20139.","DOI":"10.1016\/j.urology.2012.03.067"},{"issue":"5","key":"68_CR33","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.juro.2010.06.148","volume":"184","author":"A Stenzl","year":"2010","unstructured":"Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1907\u201313.","journal-title":"J Urol."},{"issue":"3","key":"68_CR34","first-page":"285","volume":"30","author":"SP Lerner","year":"2012","unstructured":"Lerner SP, Liu H, Wu M-F, et al. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol. 2012;30(3):285\u20139.","journal-title":"Urol."},{"issue":"5","key":"68_CR35","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","volume":"64","author":"M Burger","year":"2013","unstructured":"Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846\u201354.","journal-title":"Eur Urol."},{"issue":"1","key":"68_CR36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/01.ju.0000060782.52358.04","volume":"170","author":"P Jichlinski","year":"2003","unstructured":"Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer: a multicenter study. J Urol. 2003;170(1):226\u20139.","journal-title":"J Urol."},{"issue":"1","key":"68_CR37","first-page":"123","volume":"52","author":"O Dr\u0103goescu","year":"2011","unstructured":"Dr\u0103goescu O, Tomescu P, Panus A, et al. Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid. Rom J Morphol Embryol. 2011;52(1):123\u20137.","journal-title":"Rom J Morphol Embryol."},{"issue":"6","key":"68_CR38","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1089\/end.2008.0642","volume":"23","author":"ER Ray","year":"2009","unstructured":"Ray ER, Chatterton K, Thomas K, et al. Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer. J Endourol. 2009;23(6):983\u20138.","journal-title":"J Endourol."},{"issue":"1","key":"68_CR39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.juro.2012.03.007","volume":"188","author":"HB Grossman","year":"2012","unstructured":"Grossman HB, Stenzl A, Fradet Y, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol. 2012;188(1):58\u201362.","journal-title":"J Urol."},{"key":"68_CR40","unstructured":"Bennison C, Tempest F, Marteau A, et al. Benefit of hexaminolevulinate (HAL) technology for patients and healthcare systems in non-muscle invasive bladder cancer (NMIBC) in Italy. 10th Health Technology Assessment International; 17\u201319 Jun 2013; Seoul."},{"issue":"2","key":"68_CR41","first-page":"6682","volume":"20","author":"SS Garfield","year":"2013","unstructured":"Garfield SS, Gavaghan MB, Armstrong SO, et al. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5\u00a0years of follow up after a single hexaminolevulinate hydrochloride instillation. Can J Urol. 2013;20(2):6682\u20139.","journal-title":"Can J Urol."},{"issue":"3","key":"68_CR42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/00365590902808541","volume":"43","author":"P-U Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m P-U, Hedelin H, Thomas YK, et al. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol. 2009;43(3):192\u20138.","journal-title":"Scand J Urol Nephrol."},{"issue":"9","key":"68_CR43","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1399-6576.2006.01110.x","volume":"50","author":"L Colapaoli","year":"2006","unstructured":"Colapaoli L, Thorsen J, Nopp A, et al. A case of anaphylactic shock possibly caused by intravesical Hexvix. Acta Anaesthesiol Scand. 2006;50(9):1165\u20137.","journal-title":"Acta Anaesthesiol Scand."},{"issue":"1","key":"68_CR44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2012.08.061","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Oosterlinck W, Konety B, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):36\u201344.","journal-title":"Eur Urol."},{"issue":"3","key":"68_CR45","first-page":"6269","volume":"19","author":"S Gravas","year":"2012","unstructured":"Gravas S, Efstathiou K, Zachos I, et al. Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinate hydrochloride? Can J Urol. 2012;19(3):6269\u201373.","journal-title":"Can J Urol."},{"issue":"6","key":"68_CR46","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1464-410X.2012.10834.x","volume":"110","author":"A Roy","year":"2012","unstructured":"Roy A, Pal P, Arya M, et al. Photodynamic diagnostic cystoscopy. BJU Int. 2012;110(6):914\u20137.","journal-title":"BJU Int."},{"issue":"6","key":"68_CR47","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1464-410X.2009.08839.x","volume":"105","author":"ER Ray","year":"2010","unstructured":"Ray ER, Chatterton K, Khan MS, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. BJU Int. 2010;105(6):789\u201394.","journal-title":"BJU Int."},{"issue":"6","key":"68_CR48","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.urology.2009.06.088","volume":"74","author":"M Burger","year":"2009","unstructured":"Burger M, Stief CG, Zaak D, et al. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology. 2009;74(6):1282\u20136.","journal-title":"Urology."},{"issue":"6","key":"68_CR49","first-page":"602","volume":"20","author":"K Li","year":"2013","unstructured":"Li K, Lin T, Fan X, et al. Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. In J Urol. 2013;20(6):602\u20139.","journal-title":"In J Urol."},{"key":"68_CR50","doi-asserted-by":"crossref","unstructured":"Zheng C, Lv Y, Zhong Q, et al. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int. 2012;110(11 Pt B):E680\u20137.","DOI":"10.1111\/j.1464-410X.2012.11500.x"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-013-0068-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40291-013-0068-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-013-0068-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T22:23:42Z","timestamp":1559514222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40291-013-0068-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,19]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["68"],"URL":"https:\/\/doi.org\/10.1007\/s40291-013-0068-x","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,19]]}}}